Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection
Marc Scherlinger(Université de Strasbourg), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Sabrina Bibi‐Triki(Inserm), Floriane Gallais(Inserm), Sophie Trouillet‐Assant(Université Claude Bernard Lyon 1), Seiamak Bahram(Inserm), Alexandre Bélot(Université Claude Bernard Lyon 1), Luc Pijnenburg(Hôpitaux Universitaires de Strasbourg), Pierre Vidailhet(Hôpitaux Universitaires de Strasbourg), Magali Perret(Université Claude Bernard Lyon 1), Raphaël Carapito(Inserm), Rachel Arnould-Michel, Renaud Felten(Centre National de la Recherche Scientifique), Emmanuel Chatelus(Laboratoire National de Référence), Laurent Arnaud(Université Libre de Bruxelles), Samira Fafi‐Kremer(Centre National de la Recherche Scientifique), Jacques‐Eric Gottenberg(Centre National de la Recherche Scientifique), Amaury C. Mengin(Hôpitaux Universitaires de Strasbourg), A Gras(Hôpitaux Universitaires de Strasbourg), Charlotte Nazon
Cited by 78
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
|Autoimmunity Reviews|2020|693
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study
|Radiology|2020|472